{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:13:27Z","timestamp":1788484407031,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270224"],"award-info":[{"award-number":["82270224"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570261"],"award-info":[{"award-number":["82570261"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200169"],"award-info":[{"award-number":["82200169"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270162"],"award-info":[{"award-number":["82270162"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012401","name":"Beijing Science and Technology Planning Project","doi-asserted-by":"publisher","award":["Z251100004625001"],"award-info":[{"award-number":["Z251100004625001"]}],"id":[{"id":"10.13039\/501100012401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["202604841165"],"award-info":[{"award-number":["202604841165"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2507800"],"award-info":[{"award-number":["2023YFC2507800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218766","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:18:21Z","timestamp":1785169101000},"page":"218766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic-drug-monitoring-based ATG Targeted Dosing Strategy in Unmanipulated Haploidentical Haematopoietic Stem Cell Transplantation: a randomized, multicenter, phase 3 clinical trial"],"prefix":"10.1016","volume":"658","author":[{"given":"Liping","family":"Dou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-6952","authenticated-orcid":false,"given":"Jaap Jan","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7102-7521","authenticated-orcid":false,"given":"Haitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3334-9113","authenticated-orcid":false,"given":"Daihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218766_bib1","first-page":"629","article-title":"Clinical outcomes of three haploidentical transplantation protocols for hematologic malignancies based on data from the Chinese Bone Marrow Transplantation Registry Group","volume":"110","author":"Xu","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2026.218766_bib2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.18483","volume":"200","author":"Zhang","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2026.218766_bib3","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood.2019000487","article-title":"Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation","volume":"134","author":"Battipaglia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218766_bib4","article-title":"Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation","volume":"14","author":"Kim","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218766_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106371","article-title":"Influence of anti-thymocyte globulin plasma levels on outcome parameters in stem cell transplanted children","volume":"83","author":"Vogelsang","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2026.218766_bib6","article-title":"Optimizing anti-thymocyte globulin dosing in allogeneic hematopoietic stem cell transplantation: individualized approaches and clinical implications","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218766_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217264","article-title":"Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update","volume":"605","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218766_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.865170","article-title":"Features of epstein-barr virus and cytomegalovirus reactivation in acute leukemia patients after Haplo-HCT with myeloablative ATG-containing conditioning regimen","volume":"12","author":"Ru","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.canlet.2026.218766_bib9","doi-asserted-by":"crossref","first-page":"7765","DOI":"10.3390\/jcm12247765","article-title":"Evaluating the impact of post-transplant cyclophosphamide and anti-thymocyte globulin on CMV reactivation following allogeneic hematopoietic stem cell transplantation: a systematic literature review","volume":"12","author":"Dybko","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2026.218766_bib10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.cpt.2025.12.001","article-title":"Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein-Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD)","volume":"4","author":"Qian","year":"2026","journal-title":"Cancer Pathog. Ther."},{"key":"10.1016\/j.canlet.2026.218766_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2022.105106","article-title":"Effective Letermovir Prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: results from the French temporary authorization of use compassionate program","volume":"148","author":"Beauvais","year":"2022","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.canlet.2026.218766_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218766_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.732826","article-title":"CMV infection and CMV-specific immune reconstitution following haploidentical stem cell transplantation: an update","volume":"12","author":"Luo","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218766_bib14","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/21505594.2016.1221022","article-title":"CMV-specific immune reconstitution following allogeneic stem cell transplantation","volume":"7","author":"Blyth","year":"2016","journal-title":"Virulence"},{"key":"10.1016\/j.canlet.2026.218766_bib15","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(17)30029-7","article-title":"Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis","volume":"4","author":"Admiraal","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.canlet.2026.218766_bib16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12916-019-1393-7","article-title":"Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study","volume":"17","author":"Lin","year":"2019","journal-title":"BMC Med."},{"key":"10.1016\/j.canlet.2026.218766_bib17","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/bmt.2013.191","article-title":"Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial","volume":"49","author":"Wang","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.canlet.2026.218766_bib18","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/ajh.27068","article-title":"Targeted dosing of anti-thymocyte globulin in adult unmanipulated haploidentical peripheral blood stem cell transplantation: a single-arm, phase 2 trial","volume":"98","author":"Wang","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2026.218766_bib19","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/S2352-3026(21)00375-6","article-title":"Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial","volume":"9","author":"Admiraal","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.canlet.2026.218766_bib20","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.canlet.2026.218766_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cpt.2025.04.001","article-title":"Reduced cytomegalovirus reactivation and viremia without increasing GVHD after URD-PBSCT: a prospective study using targeted ATG dosing strategy","volume":"4","author":"Chen","year":"2026","journal-title":"Cancer Pathog. Ther."},{"key":"10.1016\/j.canlet.2026.218766_bib22","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbmt.2018.12.065","article-title":"Rabbit antithymocyte globulin serum levels: factors impacting the levels and clinical outcomes impacted by the levels","volume":"25","author":"Jamani","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.canlet.2026.218766_bib23","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00277-021-04521-z","article-title":"Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience","volume":"100","author":"Butera","year":"2021","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canlet.2026.218766_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221079739","article-title":"Lower absolute lymphocyte count before conditioning predicts high relapse risk in patients after haploidentical peripheral blood stem cell transplantation with low dose anti-thymocyte Globulin\/post-transplant cyclophosphamide for GvHD prophylaxis","volume":"31","author":"Zhou","year":"2022","journal-title":"Cell Transplant."},{"key":"10.1016\/j.canlet.2026.218766_bib25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jcyt.2024.02.015","article-title":"High-dose individualized antithymocyte globulin with therapeutic drug monitoring in high-risk cord blood transplant","volume":"26","author":"Admiraal","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.canlet.2026.218766_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.03.018","article-title":"Optimal active anti-thymocyte globulin exposure associated with minimum risk of virus reactivation and comparable acute graft-versus-host disease under adult myeloablative haploidentical peripheral blood stem cell transplantation","volume":"28","author":"Wang","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.canlet.2026.218766_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The consensus from the Chinese society of hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update","volume":"14","author":"Zhang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218766_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217594","article-title":"Comparable survival outcomes in HLA-matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40-50: a CBMTR registry-based propensity score matching analysis over the last decade","volume":"621","author":"Xu","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218766_bib29","first-page":"1023","article-title":"Patients beyond the optimal range of rATG-AUC still benefit from the targeted dosing strategy in unmanipulated Haplo-PBSCT, transplant cell","volume":"30","author":"Du","year":"2024","journal-title":"Therapy"},{"key":"10.1016\/j.canlet.2026.218766_bib30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jcyt.2020.05.005","article-title":"Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation","volume":"22","author":"van Roessel","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.canlet.2026.218766_bib31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/cpt.621","article-title":"Predicting CD4 T-Cell reconstitution following pediatric hematopoietic stem cell transplantation","volume":"102","author":"Hoare","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2026.218766_bib32","article-title":"Impact of post-transplant cyclophosphamide with bendamustine on immune reconstitution in young patients undergoing T-cell replete haploidentical bone marrow transplantation: results from a phase Ia\/Ib clinical trial","volume":"16","author":"Baker","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218766_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123318","article-title":"Combined analysis of early CD4(+) T cell counts and CMV serostatus may improve CMV risk assessment after allogeneic hematopoietic cell transplantation","volume":"10","author":"Leserer","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218766_bib34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3324\/haematol.2014.113415","article-title":"Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation","volume":"100","author":"Itzykson","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2026.218766_bib35","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00277-021-04642-5","article-title":"Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes: EBV and CMV reactivation post allo-HCT in NHL","volume":"100","author":"Ding","year":"2021","journal-title":"Ann. Hematol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:43:02Z","timestamp":1788482582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526005306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":35,"alternative-id":["S0304383526005306"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218766","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic-drug-monitoring-based ATG Targeted Dosing Strategy in Unmanipulated Haploidentical Haematopoietic Stem Cell Transplantation: a randomized, multicenter, phase 3 clinical trial","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218766","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218766"}}